Drug Trial Radar · NCT06648850
Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,120
Planned (sponsor's estimate)
Start
May 1, 2026
Primary completion
Mar 19, 2027
Study completion Apr 26, 2027
Sponsor
- Lead sponsor
- Applied Biology, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Follea International Limited; Daniel Alain, Inc.
- First posted
- Oct 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth
Conditions
- Telogen Effluvium
- Female Pattern Hair Loss
- Female Pattern Hair Loss, Androgenic Alopecia
- Male Pattern Baldness
- Androgenetic Alopecia
- Androgenetic Alopecia (AGA)
Interventions
DA-001Drug
Phenylephrine 2.5% Topical + TAAR Agonist (GRAS) Topical Solution
PlaceboOther
Placebo Topical Solution
PhenylephrineDrug
Phenylephrine 2.5% Topical
DA-001 Topical + DA-005 Oral (HIF-1α supplement)Other
DA-001 Topical (Phenylephrine 2.5% Topical + TAAR agonist tyramine) + DA-005 Oral (HIF-1α supplement)
DA-010 - Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement)Other
Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement)
Phenylephrine Topical 0.25% + Intact Pro TopicalDrug
Phenylephrine 0.25% + Intact Pro (50% stronger)
Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement)Other
Phenylephrine 0.25% + Intact Pro (50% stronger) + DA-005 Oral (HIF-1α supplement)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in Hair SheddingTime frame: Minutes [0,5]
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.